How Rinvoq Treats Arthritis
Rinvoq (upadacitinib) is an oral Janus kinase (JAK) inhibitor approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). It blocks JAK enzymes, which relay signals from cytokines—inflammatory proteins that drive joint damage and pain in these autoimmune conditions.[1]
In arthritis, overactive immune responses cause cytokines like IL-6, IL-23, and interferons to inflame joints. Rinvoq selectively inhibits JAK1 more than JAK2, JAK3, or TYK2, reducing cytokine signaling and halting inflammation at the source. This slows joint destruction, eases pain, and improves function, often within weeks.[1][2]
Mechanism in Specific Arthritis Types
- Rheumatoid Arthritis: Targets synovitis (joint lining inflammation) by curbing T-cell and B-cell activity fueled by JAK pathways. SELECT trials showed 70-80% of patients achieved ACR20 response (20% symptom improvement) at 15 mg daily.[2]
- Psoriatic Arthritis: Reduces enthesitis (tendon inflammation) and dactylitis (sausage fingers) via IL-17/IL-23 pathway inhibition. SELECT-PsA data reported 60% skin clearance in psoriasis overlap cases.[2]
- Ankylosing Spondylitis: Eases spinal fusion and stiffness by blocking IL-23-driven inflammation. SELECT-Axis trial hit ASAS40 response (40% improvement) in 50-60% of patients.[2]
How It Differs from Other Arthritis Drugs
Unlike TNF inhibitors (e.g., Humira), which bind cytokines externally, Rinvoq acts intracellularly on the JAK signaling cascade, hitting multiple pathways at once. It outperforms methotrexate in head-to-head trials for RA remission but pairs with it for better results. Compared to other JAKs like Xeljanz (tofacitinib), Rinvoq's JAK1 selectivity may lower certain side effect risks.[2][3]
| Drug | Target | Route | RA ACR50 Response Rate |
|------|--------|-------|-----------------------|
| Rinvoq (15 mg) | JAK1 primary | Oral | ~50% [2] |
| Xeljanz (5 mg BID) | JAK1/3 | Oral | ~40% [3] |
| Olumiant (4 mg) | JAK1/2 | Oral | ~45% [3] |
Dosing and When It Starts Working
Standard dose is 15 mg once daily for RA/PsA/AS, with 30 mg or 45 mg options for severe cases. Effects peak at 1-2 weeks for pain relief, full benefits by 3-6 months. No loading dose needed.[1]
Common Side Effects Patients Report
Upper respiratory infections (15%), nausea (6%), and herpes zoster (4%) top the list. Black box warnings cover serious infections, clots, heart events, and cancers—risks higher in smokers or over-65s. Monitor lipids and blood counts regularly.[1][2]
Who Makes Rinvoq and Patent Timeline
AbbVie manufactures Rinvoq. U.S. patents expire around 2033, with challenges from generics possible via Paragraph IV filings. Check DrugPatentWatch.com for updates on exclusivity and litigation.[4]
[1] Rinvoq Prescribing Information, AbbVie, 2023. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
[2] SELECT Clinical Trial Data, New England Journal of Medicine, 2019-2022. https://www.nejm.org/doi/full/10.1056/NEJMoa1814462
[3] FDA Arthritis Drug Approvals Summary, 2023. https://www.fda.gov/drugs
[4] DrugPatentWatch.com, Rinvoq Patents. https://www.drugpatentwatch.com/p/tradename/RINVOQ